ALPHAGAN P SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

BRIMONIDINE TARTRATE

可用日期:

ABBVIE CORPORATION

ATC代码:

S01EA05

INN（国际名称）:

BRIMONIDINE

剂量:

0.15%

药物剂型:

SOLUTION

组成:

BRIMONIDINE TARTRATE 0.15%

给药途径:

OPHTHALMIC

每包单位数:

3/5/10ML

处方类型:

Prescription

治疗领域:

ALPHA-ADRENERGIC AGONISTS

產品總結:

Active ingredient group (AIG) number: 0131859003; AHFS:

授权状态:

APPROVED

授权日期:

2003-11-04

产品特点

_ALPHAGAN P (brimonidine tartrate) _
_Page 1 of 26 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ALPHAGAN P®
brimonidine tartrate ophthalmic solution
Solution, 0.15% w/v, for ophthalmic use
Relatively Selective α
2
-Adrenoceptor Agonist
ATC code: S01EA05
AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, Quebec
H4S 1Z1
Submission Control Number: 266495
Date of Initial Authorization:
NOV 04, 2003
Date of Revision:
AUG
25, 2022
_ALPHAGAN P (brimonidine tartrate) _
_Page 2 of 26 _
RECENT MAJOR LABEL CHANGES
None at the time of the most recent authorization.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
4
4.1
Dosing Considerations
.............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
........................................................ 4
4.4
Administration
.........................................................................................................
5
4.5
Missed Dose
...